Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for Renilon 7.5 returned no results
Showing 136 to 150 of 168 results for region 7

  1. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)

    Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.

  2. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

  3. Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)

    Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.

  4. Transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia (HTG737)

    Evidence-based recommendations on transperineal laser ablation for treating lower urinary tract symptoms of benign prostatic hyperplasia. This involves using laser energy to destroy some of the prostate tissue.

  5. Methods for the development of NICE public health guidance (third edition) (PMG4)

    This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance

  6. Spesolimab for treating generalised pustular psoriasis flares (TA1070)

    Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.

  7. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (TA1030)

    Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.

  8. Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374)

    Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

  9. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

  10. Digital technologies for the detection of melanoma (MIB311)

    NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .

  11. Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

    Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.

  12. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTG695)

    Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.

  13. Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

    Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.

  14. microINR for anticoagulation therapy (MIB257)

    NICE has developed a medtech innovation briefing (MIB) on microINR for anticoagulation therapy .

  15. MRI-based technologies for assessing non-alcoholic fatty liver disease (HTG655)

    Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.